Rare disease treatment and gene therapy were the topics of a State of Reform 5 Slides We’re Discussing panel. Gene therapy is a form of treatment where genes are inserted into the cells of a patient, instead of relying on drugs or surgery. The therapy may be especially promising for rare diseases. Rare … Read more
Bhash Parasuraman, vice president of value and access for rare disease and internal medicine at Pfizer, joined State of Reform on Thursday for a conversation on the future of gene therapy. As part of our virtual “Leadership Series,” Parasuraman discussed the outlook for gene therapy, the policies she’d like to see to support these treatments, … Read more
A new study suggests that people with rare diseases face much higher health care costs than those without a rare disease. The study was led by the National Institute of Health and published on Oct. 21. It found that over a 15 year period, the cost per patient per year for a patient with a … Read more
In case you missed it, Early Bird Registration is now open for the 2022 Washington State of Reform Health Policy Conference coming up on January 6! We want to extend a huge thank you to our Convening Panel which met yesterday to talk through the issues and topics that will be teed up for discussion at the event. We are … Read more
Gene therapy represents a new generation of medicine that shows great promise in the fight against rare genetic diseases. The potential long-term transformative benefits could reduce, or even eliminate the ongoing costs of supporting patients and managing diseases. State of Reform is looking forward to exploring this issue in depth at our upcoming “5 Slides: Gene … Read more